Clinical Trial Update: Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency [Phase 1]

View source ↗

Summary

A Phase 1 pilot study evaluating the combination of navigated focused ultrasound and pembrolizumab for recurrent glioblastoma with mismatch repair deficiency; n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Navigated Focused Ultrasound

Snippet

Sponsor: Jennifer Leddon | Conditions: Glioblastoma, Mismatch Repair Deficiency | Phase 1 | Status: NOT_YET_RECRUITING